Replies to post #114942 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

The Australians funded the n=32 trial. They also requested an additional 104 weeks extension trial on behalf of the patients and care givers.

Would it not be reasonable, assuming results still appear promising, that they would find the money for a 300 patients trial that could just result in improved care and commensurate future savings, not to mention the ethical bonuses?

I think so despite your research findings.

[OFP]

Looks like they've contributed 9.5 weeks of Missling compensation equivalents in the past 9 months (aka $2million)

During the three and nine months ended June 30, 2017, the Company received other income of $Nil and $2,022,902, respectively (2016: $Nil and $571,093, respectively) in respect of a research and development incentive program offered by the Australian government.

However, I'm not sure this is received as cash. Their description of this program suggests it may be at least part tax incentive/offset

The Company participates, through its subsidiary in Australia, in the Australian government’s research and development incentive program. The research and development incentive program provides a refundable tax offset to eligible companies that engage in research and development activities in Australia. The Company recognizes as other income the amount received for qualified expenses, in the period they are received.

The largest reason for the increase in other income was the receipt of $2.0 million in other income as part of a research and development incentive program offered by the Australian Tax Office, which was granted in connection with eligible expenditures from our clinical trials in Australia.

I don't see anything to suggest they've been promised a grant in addition to this incentive program. Anyone know otherwise?

https://fintel.io/doc/www.sec.gov/Archives/edgar/data/1314052/000161577417004118/s107029_10q.htm